The manufacture of the Covid-19 vaccine will be carried out in the Chinese facilities of that company and will be used to immunize more than 50 million people, the Public Relations service of the Russian Fund pointed out. By late March, China’s Shenzhen Yuanxing Gene-tech Co. also agreed to produce 60 million doses of the Sputnik V vaccine to fight the SARS-CoV-2 coronavirus, which causes the disease, in conjunction with the RDIF, which financed the development of the medicine.
The new contract establishes the commitment by the RDIF and Hualan Biological Bacterin to a long-term partnership in production.
RDIF Chief Executive Kirill Dmitriev commented that the agreement with one of China’s leading vaccine manufacturers will help significantly to increase the manufacturing capabilities of the Sputnik V vaccine.
To date, the Sputnik V vaccine has been certified in 60 countries, accounting for a total population of three billion people.